A Study on The Potential of Aleglitazar to Reduce Cardiovascular Risk in Patients With Stable Cardiovascular Disease and Glucose Abnormalities

Inclusion Criteria: * Male and female patients with established evidence of stable cardiovascular disease (CVD) defined as at least one of the following groups of criteria (A or B) A. Age \>/= 40 years with history with prior CV event of prior myocardial infarction or prior ischemic stroke (confirmed by brain imaging study), with onset \>/= 3 months prior to randomization and stable in the Investigator's judgment B. Age \>/= 55 years with evidence of CVD (stable in the Investigator's judgment), defined as at least one of the following: Coronary disease, cerebrovascular disease or peripheral arterial disease as defined by protocol * Patients with glucose abnormalities based on one of the following A-B criteria: A. Established Type 2 diabetes mellitus (T2D) according to 2010 ADA criteria; treatment may include diet alone, or any glucose-lowering therapies except for thiazolidinediones (TDZs) B. No fulfillment of criterion A) but evidence of glucose abnormalities * Optimal management of CV risk factors including hypertension and dyslipidemia as informed by the best evidence and clinical practice guidelines Exclusion Criteria: * Current treatment with a thiazolidinedione (TDZ) or fibrate * Prior intolerance to a TDZ or fibrate * Previous participation in a trial with aleglitazar * Other types of diabetes * Inadequate liver, hematologic or renal function * Symptomatic heart failure classified as NYHA class II-IV * Hospitalization for a primary diagnosis of heart failure in the 12-month period preceding randomization * Peripheral edema which in the judgment of the Investigator in believed to be severe and of cardiac origin * History of surgical coronary revascularization (CABG) less than 5 years prior to screening, except in cases of subsequent myocardial infarction * Currently scheduled for arterial revascularization procedures * Systemic corticosteroid therapy for \> 2 weeks within 3 months prior to screening * Diagnosed or treated malignancy (except for treated basal cell skin cancer, in situ carcinoma of the cervix, or in situ prostate cancer) within the past 5 years